Lindsey Carr, Editor

A look at what's coming to Contemporary OB/GYN this week

A look back on this week's news.

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

Because the treatment options for imminent extreme premature labor center largely on patient preference, decision aids (DA) can help facilitate the patient-provider discussion and guide the shared decision-making process.

CooperSurgical, Inc, a global provider of health products for women, babies, and families, announced Monday plans to acquire the Reproductive Health division of Cook Medical, a manufacturer for minimally invasive medical devices in the fertility, obstetrics, and gynecology markets.

An oral concurrent session at SMFM’s 42nd Annual Pregnancy Meeting highlighted an analysis of pregnancy outcomes after optimal prenatal opioid use disorder care.

An oral presentation at the Society for Maternal-Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting explored possible associations with marijuana use and nausea and vomiting in early pregnancy.

A look at what's coming to Contemporary OB/GYN® this week.

It was a busy week for the Contemporary OB/GYN® team.

At the Society for Maternal-Fetal Medicine’s 42nd Annual Meeting, a roundtable discussion explored ways to promote inclusivity and support transgender and gender-expansive individuals in the women’s health space.

Through its new Visiting Scientist Program and Digital Innovation Fellowship, Maven aims to improve its care model and continue improving prenatal health outcomes.

The campaign emphasizes the importance of annual cancer screenings with the Queen of Hip-Hop Soul

The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.

A look at what's coming to Contemporary OB/GYN® this week.

It's been a busy week for the Contemporary OB/GYN® team. Here's a look at what you missed.

A look at what's coming to Contemporary OB/GYN® this week.

Agile Therapeutics, Inc. recently announced a new alliance with Afaxys Pharma, LLC to promote levonorgestrel and ethinyl estradiol (Twirla) transdermal system.

Here's what you missed this week from Contemporary OB/GYN®.

Here's what's coming to Contemporary OB/GYN® this week.

Here's what you missed this week from Contemporary OB/GYN®

Often based on racial/ethnic, socioeconomic, and age-based assumptions

Provider bias—stereotyped and prejudiced assumptions about patients and their “best interests”—can unintentionally harm your patients.

What's coming to Contemporary OB/GYN® this week.

A study published January 6, 2022 showed that COVID-19 vaccinations may temporarily cause changes to the timing of menstruation.

What you missed this week in women's health

An experimental blood test uses plasma cell-free RNA (cfRNA) to accurately predict preeclampsia as early as 16 weeks

Much innovation has taken place in the field of minimally invasive gynecologic surgery in the last decade. Enthusiasm for single-port surgery has waned over the past decade, due to factors like Reimbursement issues and technical demand led to a decrease in enthusiasm, but robotics companies continue to develop new solutions.

The use of hair dyes, bleach, relaxers, and mousse was associated with lower levels of sex steroid hormones in pregnant women, according to a new Rutgers study.

A look at what's coming to Contemporary OB/GYN® this week

Each year, the Medical Economics® team surveys their audience to find out what big challenges practitioners faced. By far, the top answer was “administrative burdens,” including staffing, prior authorizations and electronic health records (EHRs). Let's take a closer look at what these burdens entail to help physicians get ready for whatever challenges 2022 will bring.